Active	Status	Sponsor type	Region	Phase	Filter
9 Active 1 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vancheri, C
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Staubach, Petra
SCALP2, NCT05914805: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss	Recruiting	3	726	Europe, US	Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle	Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research	Alopecia, Androgenetic	08/24	03/25
Drees, Philipp
ENABLE-Hip, NCT06611319: ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty	Recruiting	3	2932	Europe	Prevention of Venous Thromboembolism, Rivaroxaban, Xarelto, anticoag, Direct oral anticoagulant, DOAC, Placebo Oral Tablet	Prof. Stavros Konstantinides, MD	Hip Arthroplasty, Total, Prevention of Venous Thromboembolism	03/27	07/27
NCT03289754: A Prospective Study to Evaluate the iTotal Knee and iPoly XE Tibial Inserts	Terminated	N/A	52	Europe	iPoly XE tibial insert with ConforMIS iTotal KRS	Restor3D	Knee Osteoarthritis	06/22	06/22
NCT04728542: ORIGIN® vs. VANGUARD® PS Observational Study	Recruiting	N/A	140	Europe	ORIGIN PS System, VANGUARD PS System	Symbios Orthopedie SA	Arthroplasty, Replacement, Knee	02/25	02/27
Eckhard, Lukas
NCT04728542: ORIGIN® vs. VANGUARD® PS Observational Study	Recruiting	N/A	140	Europe	ORIGIN PS System, VANGUARD PS System	Symbios Orthopedie SA	Arthroplasty, Replacement, Knee	02/25	02/27
Reshetnykova, T
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Luppi, F
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER	Recruiting	2	160	Europe, Canada, RoW	nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg	Trevi Therapeutics	Idiopathic Pulmonary Fibrosis	04/25	04/25
Drees, Philippe
NCT04728542: ORIGIN® vs. VANGUARD® PS Observational Study	Recruiting	N/A	140	Europe	ORIGIN PS System, VANGUARD PS System	Symbios Orthopedie SA	Arthroplasty, Replacement, Knee	02/25	02/27